Case45

Case45 has developed an AI prognostication model that considers cancer ecology which measures a patient's immune response to the tumor. The company relies on digital images of histology slides, which are standard for diagnosing cancer. It works with any type of lab machinery. Case45 will analyze the data (a typical slide will have more than 1 million cells of different types present) and return the results to the clinic in minutes. The algorithm considers various factors by identifying and counting different cell types and their spatial relations. One crucial element is the analysis of immune infiltration—how many immune cells are present in the tumor and adjacent to it? (Tumor-infiltrating lymphocytes or TIL). Furthermore, the algorithm can detect the evolution history of the cancer by identifying “hot” and “cold” areas that are less or more infiltrated by immune cells.
case45 colour logo
Founders / Management Khalid AbdulJabbar, Yinyin Yuan
Sectors Digital oncology, Biotechnology
Located in London, UK
Co-Investors Modi Ventures
Follow On

LinkedIn

Sign up to receive our weekly newsletter and learn about investing in technologies that are changing the world.